108 related articles for article (PubMed ID: 2389825)
21. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys.
Angsubhakorn S; Yoksan S; Bhamarapravati N; Moe JB; Marchette NJ; Pradermwong A; Sahaphong S
Trans R Soc Trop Med Hyg; 1988; 82(5):746-9. PubMed ID: 3252595
[TBL] [Abstract][Full Text] [Related]
22. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and reactogenicity of lowered doses of rhesus rotavirus vaccine strain MMU 18006 in young children.
Rennels MB; Losonsky GA; Shindledecker CL; Hughes TP; Kapikian AZ; Levine MM
Pediatr Infect Dis J; 1987 Mar; 6(3):260-4. PubMed ID: 3033593
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.
Sun W; Cunningham D; Wasserman SS; Perry J; Putnak JR; Eckels KH; Vaughn DW; Thomas SJ; Kanesa-Thasan N; Innis BL; Edelman R
Hum Vaccin; 2009; 5(1):33-40. PubMed ID: 18670195
[TBL] [Abstract][Full Text] [Related]
25. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.
McArthur JH; Durbin AP; Marron JA; Wanionek KA; Thumar B; Pierro DJ; Schmidt AC; Blaney JE; Murphy BR; Whitehead SS
Am J Trop Med Hyg; 2008 Nov; 79(5):678-84. PubMed ID: 18981503
[TBL] [Abstract][Full Text] [Related]
26. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients.
Bancroft WH; Top FH; Eckels KH; Anderson JH; McCown JM; Russell PK
Infect Immun; 1981 Feb; 31(2):698-703. PubMed ID: 7216469
[TBL] [Abstract][Full Text] [Related]
27. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids.
Morrill JC; Mebus CA; Peters CJ
Am J Vet Res; 1997 Oct; 58(10):1110-4. PubMed ID: 9328663
[TBL] [Abstract][Full Text] [Related]
28. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
Durbin AP; Karron RA; Sun W; Vaughn DW; Reynolds MJ; Perreault JR; Thumar B; Men R; Lai CJ; Elkins WR; Chanock RM; Murphy BR; Whitehead SS
Am J Trop Med Hyg; 2001 Nov; 65(5):405-13. PubMed ID: 11716091
[TBL] [Abstract][Full Text] [Related]
29. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells.
Halstead SB; Eckels KH; Putvatana R; Larsen LK; Marchette NJ
Am J Trop Med Hyg; 1984 Jul; 33(4):679-83. PubMed ID: 6476215
[TBL] [Abstract][Full Text] [Related]
30. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.
Kanesa-Thasan N; Edelman R; Tacket CO; Wasserman SS; Vaughn DW; Coster TS; Kim-Ahn GJ; Dubois DR; Putnak JR; King A; Summers PL; Innis BL; Eckels KH; Hoke CH
Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):17-23. PubMed ID: 14740951
[TBL] [Abstract][Full Text] [Related]
31. Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis.
Angsubhakorn S; Yoksan S; Pradermwong A; Nitatpattana N; Sahaphong S; Bhamarapravati N
Southeast Asian J Trop Med Public Health; 1994 Sep; 25(3):554-9. PubMed ID: 7777925
[TBL] [Abstract][Full Text] [Related]
32. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.
Durbin AP; McArthur J; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
Hum Vaccin; 2006; 2(4):167-73. PubMed ID: 17012875
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
34. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS
BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822
[TBL] [Abstract][Full Text] [Related]
35. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses.
Fine DL; Roberts BA; Teehee ML; Terpening SJ; Kelly CL; Raetz JL; Baker DC; Powers AM; Bowen RA
Vaccine; 2007 Feb; 25(10):1868-76. PubMed ID: 17240002
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle.
Morrill JC; Mebus CA; Peters CJ
Am J Vet Res; 1997 Oct; 58(10):1104-9. PubMed ID: 9328662
[TBL] [Abstract][Full Text] [Related]
37. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
38. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Blaney JE; Matro JM; Murphy BR; Whitehead SS
J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
[TBL] [Abstract][Full Text] [Related]
39. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.
Edelman R; Tacket CO; Wasserman SS; Vaughn DW; Eckels KH; Dubois DR; Summers PL; Hoke CH
J Infect Dis; 1994 Dec; 170(6):1448-55. PubMed ID: 7995984
[TBL] [Abstract][Full Text] [Related]
40. Dengue-2 vaccine: viremia and immune responses in rhesus monkeys.
Scott RM; Nisalak A; Eckels KH; Tingpalapong M; Harrison VR; Gould DJ; Chapple FE; Russell PK
Infect Immun; 1980 Jan; 27(1):181-6. PubMed ID: 6766903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
